How AI and Automation is Changing Healthcare

Terms like Artificial Intelligence (AI) and automation tend to cause two reactions: trepidation or excitement. And while AI and automation have undoubtedly blended into popular culture as tenets of sci-fi and dystopian futures, AI and automation should evoke more excitement rather than fear for what they can bring to our futures, especially in healthcare.

So, how is AI transforming the future of healthcare?

On the latest episode of the Healthcare ReThink podcast, host Brian Urban discusses the game-changing technology being introduced to healthcare with Co-Founder and COO of CloudMedx, Sahar Arshad.

The two discuss:

  • How AI is unifying the healthcare system
  • How CloudMedx uses AI and automation to improve operations and clinical outcomes
  • How AI and automation is being adopted throughout the healthcare industry

“There’s a lot of opportunity to grow in places where it can really elevate the experience for everyone—patients, providers, payers. The experience is very, very broken, right? For a patient, there’s long wait times, there’s you don’t know how much a procedure would cost, it’s just a lot of confusion, and similarly with physicians it’s the same problem, lots of documentation and administrative work…” said Arshad.

Sahar Arshad is the Co-Founder and COO of CloudMedx, a healthcare data aggregation company that puts data into a single unified platform. She has over 20 years of experience in building products that bring convenience and accessibility at scale. Prior to founding CloudMedx, Arshad worked as a woman in tech in various roles, including as a Business Analyst for Inbox Business Technologies and as the CEO of Imaginate Technologies. She has been awarded numerous industry awards, including selection as a U.S. Data Leader of the Year and U.S. Entrepreneur of the Year at the 2021 Women in IT Summit and Awards Series. She has also been named among the top 10 women leading healthcare startups by Healthcare Global and within the top 25 women leaders in consumer health tech by the Healthcare Technology Report. She earned her BS in Computer Science from the National University of Computer and Emerging Sciences.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More